Company intelligence / Profile preview

Perma-Fix Medical

Warsaw, Poland

Ownership: Private
Development stage: Other

Overview

Perma-Fix Medical has developed a proprietary, uranium-free process for producing Tc-99m, the world's most commonly used radioisotope for diagnostic imaging. The technology has successfully passed pilot testing and is advancing toward regulatory submissions, with the aim of providing a more secure, local, and proliferation-resistant supply of Tc-99m for nuclear medicine worldwide[2][4][6].

Therapeutic areas: Other
Modalities: Radiopharmaceutical
Industry: Chemicals & Materials

Partnerships

Digirad Corporation

Beyond the preview

Go deeper on Perma-Fix Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perma-Fix Medical.

Explore the full profile